A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment.

Several studies have reported that patients harboring MET-ex14 skipping benefit from MET tyrosine kinase inhibitors (TKIs) such as crizotinib, however, the overall response of crizotinib was 32% in these patients. Therefore, the clinical outcome of patients harboring different MET 14 skipping subtypes are worthy to be concern. Based on NGS analysis, we described a lung adenocarcinoma patient harboring a MET c.3028 + 2 T > A mutation which was predicted to lead to MET-ex14 skipping. Moreover, we performed IHC and qPCR to verify this variant. Then the patient treated with crizotinib and achieved good therapeutic effect. This mutation is firstly verified not only by multiple methodologies, but also by clinical effect. Our finding expands the spectrum of MET 14 exon skipping variant and maybe offer available application basis of MET inhibitor to patients harboring MET c. 3028 + 2 T > A/C/G. Importantly, targeted NGS analysis could improve detection of MET alterations in routine practice.